Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.
Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.
Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.
The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.
Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.
For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.
Bionano Genomics (BNGO) announces participation in the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022, in New Orleans. The company will showcase its optical genome mapping (OGM) solutions, NxClinical software, and laboratory services. Notable presentations include research on genomic structural variations and homologous recombination deficiency (HRD) analysis. Bionano will also introduce NxClinical version 6.2, enhancing HRD analysis capabilities. This participation aims to demonstrate the potential impact of their solutions in cancer research.
Bionano Genomics (BNGO) announced the 2022 China Symposium, scheduled for March 26, featuring 9 presentations from leading Chinese researchers on optical genome mapping (OGM) applications. Topics include human fertility, prenatal genetics, hematological disorders, and solid tumors. Key speakers include Bionano’s CEO Erik Holmlin and CMO Alka Chaubey, who will discuss highlights from the 2022 global symposium. This event underscores Bionano's global commitment to genomic discovery and expanding its community in China.
Bionano Genomics, known for its innovations in optical genome mapping, has announced that CEO Erik Holmlin will present at the 2022 Maxim Virtual Growth Conference. This event will take place on March 30, 2022, at 12:30 PM PT/3:30 PM ET. The conference can be accessed via the M-Vest platform, where participants can register and view the presentation. Bionano aims to transform genome analysis through its Saphyr® system and NxClinical™ software, addressing critical questions in biology and medicine.
Bionano Genomics is participating in the ACMG Annual Clinical Genetics Meeting from March 23–26, 2022, showcasing its complete product portfolio for the first time. Attendees will include combined teams exhibiting Optical Genome Mapping Solutions, Testing Services, and Software. Six scientific posters will discuss advancements in clinical genetics research, particularly for rare undiagnosed genetic diseases. Bionano aims to support genetic clinicians and researchers with enhanced solutions, promoting discovery and improving diagnostics for patients with genetic disorders.
Bionano Genomics (BNGO) announced the validation of its optical genome mapping (OGM) technology in detecting structural variants (SVs) in hematological neoplasms. The study, involving 59 samples, showed OGM's 98.7% sensitivity and 100% specificity, outperforming traditional methods like karyotyping and FISH. OGM also detected additional chromosomal aberrations in cases where traditional methods failed. Researchers suggested OGM as a potential first-tier test in clinical settings, enhancing the identification of new therapeutic targets. The study reflects increasing evidence for OGM's efficacy in routine use.
Bionano Genomics (BNGO) announced that its management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference. CEO Erik Holmlin is scheduled to deliver a corporate overview on March 15, 2022, at 5:40 am PT/8:40 am ET. The presentation will be accessible on Bionano’s Investors section on their website. The company specializes in optical genome mapping and offers software solutions for genomic data visualization and interpretation, aiming to revolutionize genome analysis in research and diagnostics.
Bionano Genomics (BNGO) announced the appointment of Dr. Aleks Rajkovic to its board of directors. Dr. Rajkovic, currently the Chief Genomics Officer at UCSF, brings extensive expertise in genomic medicine, including reproductive health and genetic screening. His appointment aims to enhance Bionano's efforts in expanding the capabilities of optical genome mapping (OGM) and its applications in clinical research and patient management. The company continues to focus on revolutionizing genomic analysis with its Saphyr® system and related software solutions.
Bionano Genomics (BNGO) announced that CEO Erik Holmlin will present at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 11:10 AM PT/2:10 PM ET. The presentation will provide a corporate overview and can be viewed on the company's website. Bionano is known for its optical genome mapping solutions and the NxClinical™ software, aimed at enhancing genomic data analysis and reporting. The company's mission is to transform genome analysis in clinical research, particularly in understanding genetic conditions.
Bionano Genomics reported a remarkable 111% revenue growth for full-year 2021, totaling $18.0 million, with a 58% increase to $6.3 million in Q4. The company boasts a robust balance sheet with $250.6 million in cash as of December 31, 2021. Bionano aims for 2022 revenue between $24 million and $27 million, showcasing potential growth of 33% to 50%. Significant advancements include expanding their Saphyr system installations by 69% and enhancing software capabilities through the acquisition of BioDiscovery.
Bionano Genomics (Nasdaq: BNGO) has launched a strategic initiative focused on rare undiagnosed genetic diseases (RUGD) in recognition of Rare Disease Day. Currently, over 350 million people globally are affected by rare diseases, with about 80% attributed to genetic factors. Despite advancements in genetic testing methods, more than 50% of patients remain undiagnosed. Bionano’s initiative includes support for research, educational awareness, and a three-year financial commitment to the ACMG Foundation to expand the genetic workforce. This effort aims to enhance patient care and improve diagnosis rates for rare diseases.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
What does Bionano Genomics, Inc. specialize in?
What is the Saphyr™ system?
What are the applications of Bionano's OGM technology?
What recent achievements has Bionano reported?
Where does Bionano operate?
What additional services does Bionano offer?
Who are Bionano's key partners?
What is the purpose of Bionano's VIA software?
Are Bionano's products for research or clinical use?
How can I learn more about Bionano Genomics?
